FDA approval occurred in 2022 and 2023, respectively
An important and underappreciated consideration is that following a keto or low-carb nutrition protocol alongside GLP-1 drugs, if needed, may mean lower medication doses are sufficient
While obesity itself significantly increases venous thromboembolism risk, current evidence shows these injections do not add to that risk and may actually improve cardiovascular health through weight reduction
34,35 Subsequently, GLP-1 undergoes enzymatic degradation facilitated by dipeptidyl peptidase IV (DPP-4), leading to the loss of its biological efficacy
[10] further suggested that GHK-Cu may upregulate VEGF, raise endothelial cell proliferation, and encourage endothelial migration and tube formation in laboratory models